adalimumab
Phase 3Completed 0 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Rheumatoid Arthritis
Conditions
Rheumatoid Arthritis
Trial Timeline
Aug 1, 2004 → —
NCT ID
NCT00235872About adalimumab
adalimumab is a phase 3 stage product being developed by Eisai for Rheumatoid Arthritis. The current trial status is completed. This product is registered under clinical trial identifier NCT00235872. Target conditions include Rheumatoid Arthritis.
What happened to similar drugs?
20 of 20 similar drugs in Rheumatoid Arthritis were approved
Approved (20) Terminated (0) Active (0)
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (7)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01243671 | Phase 3 | Completed |
| NCT00690573 | Phase 3 | Completed |
| NCT00667355 | Phase 3 | Completed |
| NCT00445432 | Phase 2/3 | Completed |
| NCT00603993 | Phase 3 | Completed |
| NCT00235872 | Phase 3 | Completed |
| NCT00235833 | Phase 2 | Completed |
Competing Products
20 competing products in Rheumatoid Arthritis